Skip to main content
Fig. 7 | Journal of Neuroinflammation

Fig. 7

From: Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease

Fig. 7

Change of gene expression profile in cortex of PFF-injected mice by fexofenadine. a Principal component analysis of RNA-seq data from PFF (n = 2), PFF + Fexo (n = 2), PBS (n = 2), and PBS + Fexo (n = 2) groups. b Volcano plot showing the number of upregulated (334) and downregulated (228) DEGs between PBS injection versus PFF injection (x-axis: log2(fold change); y-axis: − log10(p.value), fold change cutoff: 0.25; p.value cutoff < 0.05). c Heatmap showing top 10 genes from upregulated in PFF and downregulated in PFF + Fexo or downregulated in PFF and upregulated in PFF + Fexo. d GO analysis showing top 5 upregulated GO term (GO: BP, KEGG and Reactome) from DEGs of PFF versus PBS. Gray color indicates the number of genes rescued by fexofenadine. e Histogram showing canonical pathway by IPA of the PBS versus PFF, PFF versus PFF + Fexo, and PBS versus PBS + Fexo groups. (Bar graph: − log10 (p.value); line graph: ratio; color: Z-score.) f Histogram and heatmap showing disease and function by IPA of the PBS versus PFF, PFF versus PFF + Fexo, and PBS versus PBS + Fexo groups. g Histogram and heatmap showing upstream regulators by IPA of the PBS versus PFF, PFF versus PFF + Fexo, and PBS versus PBS + Fexo groups

Back to article page